Study on reducing liver cancer risk in hepatitis B patients
Treatments studied
Part of Digestive system, Infections clinical trials.
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B (HBsAg-positive for at least 6 months).
- You are 18 years old or older.
- You are already taking or planning to take one of these hepatitis B treatments: entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, tenofovir amibufenamide, or pegylated interferon alfa-2b (either for the first time or restarting).
- You do not have severe liver damage (decompensated cirrhosis) or liver cancer (hepatocellular carcinoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.